Back to Search Start Over

DNAM-1 promotes inflammation-driven tumor development via enhancing IFN-γ production.

Authors :
Nakamura-Shinya Y
Iguchi-Manaka A
Murata R
Sato K
Vo AV
Kanemaru K
Shibuya A
Shibuya K
Source :
International immunology [Int Immunol] 2022 Feb 23; Vol. 34 (3), pp. 149-157.
Publication Year :
2022

Abstract

DNAM-1 is an activating immunoreceptor on T cells and natural killer (NK) cells. Expression levels of its ligands, CD155 and CD112, are up-regulated on tumor cells. The interaction of DNAM-1 on CD8+ T cells and NK cells with the ligands on tumor cells plays an important role in tumor immunity. We previously reported that mice deficient in DNAM-1 showed accelerated growth of tumors induced by the chemical carcinogen 7,12-dimethylbenz[a]anthracene (DMBA). Contrary to those results, we show here that tumor development induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) together with DMBA was suppressed in DNAM-1-deficient mice. In this model, DNAM-1 enhanced IFN-γ secretion from conventional CD4+ T cells to promote inflammation-related tumor development. These findings suggest that, under inflammatory conditions, DNAM-1 contributes to tumor development via conventional CD4+ T cells.<br /> (© The Japanese Society for Immunology. 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1460-2377
Volume :
34
Issue :
3
Database :
MEDLINE
Journal :
International immunology
Publication Type :
Academic Journal
Accession number :
34672321
Full Text :
https://doi.org/10.1093/intimm/dxab099